Discovery of a Heart-Specific Receptor for Growth Hormone Peptides That Protects Against Heart Attack Damage
A new cardiac-specific GHRP receptor was identified that is distinct from the pituitary GH-releasing receptor, explaining how hexarelin protects hearts from ischemic damage independently of growth hormone.
Quick Facts
What This Study Found
A novel cardiac-specific GHRP receptor distinct from the pituitary GHS-R was identified in rat heart tissue, binding hexarelin with high affinity and mediating cardioprotective effects independently of GH release.
Key Numbers
How They Did This
Animal study using radioligand binding on cardiac membranes from normal, GH-deficient, and senescent rats. Receptor specificity was determined by competition binding with various ligands. Functional cardioprotection was confirmed in isolated heart models.
Why This Research Matters
The discovery that the heart has its own GHRP receptor means GH secretagogues could be developed specifically for cardiac protection, separate from their GH-releasing effects. This opens a new therapeutic avenue for heart disease.
The Bigger Picture
Heart disease is the leading cause of death worldwide. A peptide that directly protects the heart through its own receptor — separate from any GH effects — represents a fundamentally new approach to cardiovascular therapy.
What This Study Doesn't Tell Us
Receptor identified in rat hearts; human cardiac receptor confirmation needed. The downstream signaling pathway was not fully characterized. In-vivo cardioprotective dose-response not established.
Questions This Raises
- ?Can this cardiac receptor be targeted with selective peptides for heart protection?
- ?Does this receptor exist in human hearts?
- ?Could GHRP analogs be developed that protect the heart without raising GH?
Trust & Context
- Key Stat:
- Distinct cardiac receptor The heart's GHRP receptor is different from the pituitary receptor, meaning cardiac protection is independent of growth hormone release
- Evidence Grade:
- Moderate evidence from comprehensive binding studies with functional validation in isolated heart models, across multiple animal age groups.
- Study Age:
- Published in 1999. This cardiac GHRP receptor (later linked to CD36) has been further characterized, confirming the heart as a direct target for GH secretagogues.
- Original Title:
- Identification and characterization of a new growth hormone-releasing peptide receptor in the heart.
- Published In:
- Circulation research, 85(9), 796-802 (1999)
- Authors:
- Bodart, V(2), Bouchard, J F(2), McNicoll, N(3), Escher, E, Carrière, P, Ghigo, E, Sejlitz, T, Sirois, M G, Lamontagne, D, Ong, H
- Database ID:
- RPEP-00513
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can growth hormone peptides protect the heart?
Yes. This study shows hexarelin protects hearts from damage after blood flow loss, and it does so through a unique heart receptor — not by raising growth hormone. This means the cardiac benefit is direct and independent.
Could this lead to new heart medications?
Potentially. A peptide that directly activates cardiac protective receptors could be developed as a treatment for heart attacks or heart failure, representing a completely new class of cardiovascular drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00513APA
Bodart, V; Bouchard, J F; McNicoll, N; Escher, E; Carrière, P; Ghigo, E; Sejlitz, T; Sirois, M G; Lamontagne, D; Ong, H. (1999). Identification and characterization of a new growth hormone-releasing peptide receptor in the heart.. Circulation research, 85(9), 796-802.
MLA
Bodart, V, et al. "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart.." Circulation research, 1999.
RethinkPeptides
RethinkPeptides Research Database. "Identification and characterization of a new growth hormone-..." RPEP-00513. Retrieved from https://rethinkpeptides.com/research/bodart-1999-identification-and-characterization-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.